| RS104894206 |
CTSC
|
Health Risk |
Pathogenic |
Papillon-Lefèvre syndrome, Haim-Munk syndrome |
| RS104894207 |
CTSC
|
Health Risk |
Pathogenic/Likely pathogenic |
Papillon-Lefèvre syndrome, Periodontitis |
| RS104894208 |
CTSC
|
Health Risk |
Conflicting classifications of pathogenicity |
Haim-Munk syndrome, Papillon-Lefèvre syndrome |
| RS104894209 |
CTSC
|
Health Risk |
Pathogenic |
Papillon-Lefèvre syndrome, Periodontitis |
| RS104894210 |
CTSC
|
Health Risk |
Likely pathogenic |
Papillon-Lefèvre syndrome, Haim-Munk syndrome |
| RS104894211 |
CTSC
|
Health Risk |
Pathogenic |
Periodontitis, aggressive 1 |
| RS104894212 |
DHCR7
|
Health Risk |
Pathogenic/Likely pathogenic |
Smith-Lemli-Opitz syndrome, Smith-Lemli-Opitz syndrome |
| RS104894213 |
DHCR7
|
Health Risk |
Pathogenic |
Smith-Lemli-Opitz syndrome, Smith-Lemli-Opitz syndrome |
| RS104894214 |
CTSC
|
Health Risk |
Pathogenic/Likely pathogenic |
Papillon-Lefèvre syndrome, Haim-Munk syndrome |
| RS104894215 |
CTSC
|
Health Risk |
Pathogenic |
Papillon-Lefèvre syndrome, Papillon-Lefèvre syndrome |
| RS104894221 |
FANCF
|
Health Risk |
Pathogenic |
Fanconi anemia complementation group F, Fanconi anemia complementation group F |
| RS104894222 |
FANCF
|
Health Risk |
Pathogenic |
Fanconi anemia complementation group F, Fanconi anemia complementation group F |
| RS104894223 |
FZD4
|
Health Risk |
Conflicting classifications of pathogenicity |
Retinopathy of prematurity, FZD4-related disorder |
| RS104894226 |
HRAS
|
Health Risk |
Pathogenic/Likely pathogenic |
Costello syndrome, RASopathy |
| RS104894227 |
HRAS
|
Health Risk |
Pathogenic |
Costello syndrome, RASopathy |
| RS104894228 |
HRAS
|
Health Risk |
Likely pathogenic |
Costello syndrome, RASopathy |
| RS104894229 |
HRAS
|
Health Risk |
Likely pathogenic |
Costello syndrome, Myopathy |
| RS104894230 |
HRAS;LRRC56
|
Health Risk |
Pathogenic/Likely pathogenic |
Malignant tumor of urinary bladder, Costello syndrome |
| RS104894231 |
HRAS
|
Health Risk |
Pathogenic |
Costello syndrome, Costello syndrome |
| RS104894232 |
DDX25;HYLS1;PUS3
|
Health Risk |
Pathogenic |
Hydrolethalus syndrome, Hydrolethalus syndrome 1 |
| RS104894236 |
KCNJ11
|
Health Risk |
Conflicting classifications of pathogenicity |
Hyperinsulinemic hypoglycemia, familial |
| RS104894237 |
KCNJ11
|
Health Risk |
Likely pathogenic |
Hyperinsulinemic hypoglycemia, familial |
| RS104894244 |
KCNJ1
|
Health Risk |
Conflicting classifications of pathogenicity |
Bartter disease type 2, Bartter disease type 2 |
| RS104894245 |
KCNJ1
|
Health Risk |
Likely pathogenic |
Bartter disease type 2, Bartter disease type 2 |
| RS104894246 |
KCNJ1
|
Health Risk |
Conflicting classifications of pathogenicity |
Bartter disease type 2, Bartter syndrome |
| RS104894248 |
KCNJ11
|
Health Risk |
Conflicting classifications of pathogenicity |
Hyperinsulinemic hypoglycemia, familial |
| RS104894250 |
KCNJ1
|
Health Risk |
Pathogenic |
Bartter disease type 2, Bartter disease type 2 |
| RS104894251 |
KCNJ1
|
Health Risk |
Pathogenic |
Bartter disease type 2, Bartter disease type 2 |
| RS104894253 |
KCNJ1
|
Health Risk |
Likely pathogenic |
Bartter disease type 2, Bartter syndrome |
| RS104894254 |
KCNJ1
|
Health Risk |
Likely pathogenic |
Bartter disease type 2, Bartter syndrome |
| RS104894255 |
KCNQ1
|
Health Risk |
Pathogenic/Likely pathogenic |
Congenital long QT syndrome, Long QT syndrome |
| RS104894256 |
MEN1
|
Health Risk |
Pathogenic/Likely pathogenic |
Multiple endocrine neoplasia, type 1 |
| RS104894257 |
MEN1
|
Health Risk |
Pathogenic |
Multiple endocrine neoplasia, type 1 |
| RS104894258 |
MEN1
|
Health Risk |
Pathogenic |
Multiple endocrine neoplasia, type 1 |
| RS104894259 |
MEN1
|
Health Risk |
Pathogenic/Likely pathogenic |
Multiple endocrine neoplasia, type 1 |
| RS104894260 |
MEN1
|
Health Risk |
Pathogenic |
Multiple endocrine neoplasia, type 1 |
| RS104894261 |
MEN1
|
Health Risk |
Pathogenic/Likely pathogenic |
Multiple endocrine neoplasia, type 1 |
| RS104894262 |
MEN1
|
Health Risk |
Pathogenic |
Multiple endocrine neoplasia, type 1 |
| RS104894263 |
MEN1
|
Health Risk |
Pathogenic |
Multiple endocrine neoplasia, type 1 |
| RS104894264 |
MEN1
|
Health Risk |
Pathogenic |
Multiple endocrine neoplasia, type 1 |
| RS104894265 |
MEN1
|
Health Risk |
Pathogenic |
Multiple endocrine neoplasia, type 1 |
| RS104894266 |
MEN1
|
Health Risk |
Pathogenic |
Multiple endocrine neoplasia, type 1 |
| RS104894267 |
MEN1
|
Health Risk |
Pathogenic |
Multiple endocrine neoplasia, type 1 |
| RS104894268 |
MEN1
|
Health Risk |
Conflicting classifications of pathogenicity |
Multiple endocrine neoplasia, type 1 |
| RS104894270 |
NDUFS3
|
Health Risk |
Pathogenic/Likely pathogenic |
Mitochondrial complex I deficiency, nuclear type 8 |
| RS104894271 |
PTH
|
Health Risk |
Pathogenic |
Hypoparathyroidism, familial isolated 1 |
| RS104894272 |
PTH
|
Health Risk |
Pathogenic |
Hypoparathyroidism, familial isolated 1 |
| RS104894273 |
PTS
|
Health Risk |
Pathogenic/Likely pathogenic |
6-Pyruvoyl-tetrahydrobiopterin synthase deficiency, 6-Pyruvoyl-tetrahydrobiopterin synthase deficiency |
| RS104894274 |
PTS
|
Health Risk |
Likely pathogenic |
Hyperphenylalaninemia, bh4-deficient |
| RS104894275 |
PTS
|
Health Risk |
Pathogenic |
6-Pyruvoyl-tetrahydrobiopterin synthase deficiency, PTS-related disorder |
| RS104894276 |
PTS
|
Health Risk |
Pathogenic |
6-Pyruvoyl-tetrahydrobiopterin synthase deficiency, Hyperphenylalaninemia due to tetrahydrobiopterin deficiency |
| RS104894277 |
PTS
|
Health Risk |
Pathogenic/Likely pathogenic |
6-Pyruvoyl-tetrahydrobiopterin synthase deficiency, 6-Pyruvoyl-tetrahydrobiopterin synthase deficiency |
| RS104894278 |
PTS
|
Health Risk |
Pathogenic |
Hyperphenylalaninemia, bh4-deficient |
| RS104894279 |
PTS
|
Health Risk |
Conflicting classifications of pathogenicity |
Hyperphenylalaninemia, bh4-deficient |
| RS104894280 |
PTS
|
Health Risk |
Pathogenic |
6-Pyruvoyl-tetrahydrobiopterin synthase deficiency, 6-Pyruvoyl-tetrahydrobiopterin synthase deficiency |
| RS104894281 |
NECTIN1
|
Health Risk |
Pathogenic |
Cleft lip/palate-ectodermal dysplasia syndrome, Orofacial cleft 7 |
| RS104894282 |
RAG1
|
Health Risk |
Pathogenic/Likely pathogenic |
Severe combined immunodeficiency, B cell-negative |
| RS104894283 |
RAG1
|
Health Risk |
Likely pathogenic |
Severe combined immunodeficiency, B cell-negative |
| RS104894284 |
RAG1
|
Health Risk |
Pathogenic/Likely pathogenic |
Histiocytic medullary reticulosis, Combined immunodeficiency with skin granulomas |
| RS104894285 |
RAG1
|
Health Risk |
Pathogenic |
Severe combined immunodeficiency, B cell-negative |
| RS104894286 |
RAG1
|
Health Risk |
Pathogenic/Likely pathogenic |
Histiocytic medullary reticulosis, Inherited Immunodeficiency Diseases |
| RS104894287 |
RAG1
|
Health Risk |
Pathogenic |
Combined immunodeficiency due to partial RAG1 deficiency, Severe combined immunodeficiency |
| RS104894288 |
RAG1
|
Health Risk |
Pathogenic |
Combined immunodeficiency due to partial RAG1 deficiency, Combined immunodeficiency due to partial RAG1 deficiency |
| RS104894289 |
RAG1
|
Health Risk |
Pathogenic |
Histiocytic medullary reticulosis, Severe combined immunodeficiency |
| RS104894290 |
RAG1
|
Health Risk |
Pathogenic |
Histiocytic medullary reticulosis, Histiocytic medullary reticulosis |
| RS104894291 |
RAG1
|
Health Risk |
Pathogenic |
Histiocytic medullary reticulosis, Severe combined immunodeficiency |
| RS104894292 |
RAG1
|
Health Risk |
Pathogenic |
Histiocytic medullary reticulosis, Histiocytic medullary reticulosis |
| RS104894293 |
RAPSN
|
Health Risk |
Conflicting classifications of pathogenicity |
Congenital myasthenic syndrome 11, Global developmental delay |
| RS104894294 |
RAPSN
|
Health Risk |
Pathogenic/Likely pathogenic |
Congenital myasthenic syndrome 11, Myopathy |
| RS104894295 |
SC5D
|
Health Risk |
Likely pathogenic |
Lathosterolosis, Lathosterolosis |
| RS104894296 |
SC5D
|
Health Risk |
Likely pathogenic |
Lathosterolosis, Lathosterolosis |
| RS104894297 |
SC5D
|
Health Risk |
Pathogenic |
Lathosterolosis, Lathosterolosis |
| RS104894298 |
RAG1
|
Health Risk |
Conflicting classifications of pathogenicity |
Severe combined immunodeficiency, autosomal recessive |
| RS104894299 |
RAPSN
|
Health Risk |
Pathogenic/Likely pathogenic |
Congenital myasthenic syndrome 4C, Congenital myasthenic syndrome 11 |
| RS104894300 |
RAPSN
|
Health Risk |
Pathogenic/Likely pathogenic |
Congenital myasthenic syndrome 11, Fetal akinesia deformation sequence 1 |
| RS104894301 |
RAPSN
|
Health Risk |
Pathogenic |
Congenital myasthenic syndrome 11, Congenital myasthenic syndrome 11 |
| RS104894302 |
SDHD
|
Health Risk |
Pathogenic/Likely pathogenic |
Pheochromocytoma/paraganglioma syndrome 1, Hereditary cancer-predisposing syndrome |
| RS104894303 |
SDHD
|
Health Risk |
Pathogenic |
Pheochromocytoma/paraganglioma syndrome 1, Hereditary cancer-predisposing syndrome |
| RS104894304 |
SDHD
|
Health Risk |
Pathogenic |
Pheochromocytoma/paraganglioma syndrome 1, Hereditary pheochromocytoma and paraganglioma |
| RS104894305 |
SDHD
|
Health Risk |
Pathogenic |
Pheochromocytoma/paraganglioma syndrome 1, Hereditary pheochromocytoma and paraganglioma |
| RS104894306 |
SDHD
|
Health Risk |
Pathogenic |
Pheochromocytoma/paraganglioma syndrome 1, Pheochromocytoma |
| RS104894307 |
SDHD
|
Health Risk |
Pathogenic |
Paragangliomas with sensorineural hearing loss, Cowden syndrome 3 |
| RS104894308 |
SDHD
|
Health Risk |
Pathogenic |
Pheochromocytoma/paraganglioma syndrome 1, Hereditary cancer-predisposing syndrome |
| RS104894309 |
SDHD
|
Health Risk |
Pathogenic |
Pheochromocytoma, Hereditary cancer-predisposing syndrome |
| RS104894310 |
SDHD
|
Health Risk |
Pathogenic |
Carney-Stratakis syndrome, Paragangliomas with sensorineural hearing loss |
| RS104894311 |
TNNI2
|
Health Risk |
Pathogenic |
Distal arthrogryposis type 2B1, Distal arthrogryposis type 2B1 |
| RS104894312 |
TNNI2
|
Health Risk |
Pathogenic |
Distal arthrogryposis type 2B1, Calcaneovalgus deformity |
| RS104894313 |
TYR
|
Health Risk |
Conflicting classifications of pathogenicity |
Oculocutaneous albinism type 1B, Oculocutaneous albinism |
| RS104894314 |
TYR
|
Health Risk |
Pathogenic/Likely pathogenic |
Oculocutaneous albinism type 1B, Oculocutaneous albinism type 1A |
| RS104894315 |
TYR
|
Health Risk |
Pathogenic |
Oculocutaneous albinism type 1A, SKIN/HAIR/EYE PIGMENTATION 3 |
| RS104894316 |
TYR
|
Health Risk |
Pathogenic |
Oculocutaneous albinism type 1A, Oculocutaneous albinism |
| RS104894317 |
TYR
|
Health Risk |
Pathogenic/Likely pathogenic |
Oculocutaneous albinism type 1A, Oculocutaneous albinism |
| RS104894318 |
TYR
|
Health Risk |
Pathogenic/Likely pathogenic |
Oculocutaneous albinism type 1A, SKIN/HAIR/EYE PIGMENTATION 3 |
| RS104894319 |
UCP3
|
Health Risk |
Conflicting classifications of pathogenicity |
Obesity, severe |
| RS104894321 |
AICDA
|
Health Risk |
Pathogenic |
Hyper-IgM syndrome type 2, Hyper-IgM syndrome type 2 |
| RS104894322 |
AICDA
|
Health Risk |
Pathogenic |
Hyper-IgM syndrome type 2, Hyper-IgM syndrome type 2 |
| RS104894323 |
AICDA
|
Health Risk |
Pathogenic |
Hyper-IgM syndrome type 2, Hyper-IgM syndrome type 2 |
| RS104894324 |
AICDA
|
Health Risk |
Pathogenic |
Hyper-IgM syndrome type 2, Hyper-IgM syndrome type 2 |
| RS104894325 |
AICDA
|
Health Risk |
Pathogenic |
Hyper-IgM syndrome type 2, Hyper-IgM syndrome type 2 |
| RS104894326 |
AQP2
|
Health Risk |
Pathogenic/Likely pathogenic |
Nephrogenic diabetes insipidus, Diabetes insipidus |